DDInter998 DDInter484
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Ivermectin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) downregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) downregulates {v} (Gene) PKMYT1
PKMYT1 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) ERBB3
ERBB3 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Ivermectin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) FMO3
FMO3 {u} (Gene) is bound by {v} (Compound) Dasatinib
Ivermectin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Ivermectin (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Dasatinib (Compound)
Ivermectin (Compound) downregulates LRPAP1 (Gene) and LRPAP1 (Gene) is upregulated by Dasatinib (Compound)
Ivermectin (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Dasatinib (Compound)
Ivermectin (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Dasatinib (Compound)
Ivermectin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Ivermectin (Compound) downregulates PKMYT1 (Gene) and PKMYT1 (Gene) is bound by Dasatinib (Compound) and PKMYT1 (Gene) is downregulated by Dasatinib (Compound)
Ivermectin (Compound) upregulates ERBB3 (Gene) and ERBB3 (Gene) is bound by Dasatinib (Compound) and ERBB3 (Gene) is upregulated by Dasatinib (Compound)
Ivermectin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Ivermectin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with FMO3 (Gene) and FMO3 (Gene) is bound by Dasatinib (Compound)